AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast

by Barry101 | Nov 6, 2024 | Press Release

OCALA, Fla., Nov. 06, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q3 2024 operational and financial...

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

by Barry101 | Nov 4, 2024 | Press Release

Warns Shareholders that Activist Group’s Self-Interested Agenda Could Disrupt AIM’s Momentum and Destroy Chances for Near-Term Value Creation Expresses Excitement About Encouraging Progress of Clinical Trials for Ampligen in High-Value Indications...

AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC

by Barry101 | Oct 9, 2024 | Press Release

Live webcast fireside chat on Wednesday, October 16th at 12:30 PM ETOCALA, Fla., Oct. 09, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that Tom Equels, Chief Executive Officer of AIM, will...

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

by Barry101 | Oct 3, 2024 | Press Release

OCALA, Fla., Oct. 03, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent No. 12,102,649, covering both compositions...

AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering

by Barry101 | Sep 30, 2024 | Press Release

OCALA, Fla., Sept. 30, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,653,036 shares of...